NGNE (Neurogene) Ending Cash Position: $124.50 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGNE Neurogene Inc NGNE
12 GF Score
Price $34.90
! 3 Warning Signs
View Full Analysis

What is Neurogene Ending Cash Position?

Neurogene NGNE -1.80% 12 Ending Cash Position is $124.50 Mil as of Mar. 2026. GuruFocus rates NGNE with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Neurogene's Ending Cash Position for the quarter that ended in Mar. 2026 was $124.50 Mil.

Neurogene's quarterly Ending Cash Position increased from Sep. 2025 ($71.34 Mil) to Dec. 2025 ($104.18 Mil) and increased from Dec. 2025 ($104.18 Mil) to Mar. 2026 ($124.50 Mil).

Neurogene's annual Ending Cash Position declined from Dec. 2023 ($148.72 Mil) to Dec. 2024 ($136.93 Mil) and declined from Dec. 2024 ($136.93 Mil) to Dec. 2025 ($104.18 Mil).

Neurogene Ending Cash Position Related Terms

Neurogene Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Neurogene's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurogene Ending Cash Position Chart

Neurogene Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
70.54 82.02 148.72 136.93 104.18

Neurogene Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.11 59.15 71.34 104.18 124.50
NGNE
12GF Score
Neurogene Inc NGNE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurogene Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Neurogene's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=136.925+-32.741
=104.18

Neurogene's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=104.184+20.316
=124.50

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $124.50 Mil mean?
Neurogene (NGNE) has a Ending Cash Position of $124.50 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neurogene and its competitors.
Is Neurogene's Ending Cash Position too high?
Neurogene's current Ending Cash Position is $124.50 Mil. Overall, Neurogene has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Neurogene's Ending Cash Position compare to STRO and OCGN?
Neurogene's Ending Cash Position of $124.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Neurogene and its competitors. Neurogene's current Ending Cash Position is $124.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurogene stock overvalued right now?
Neurogene (NGNE) has a current Ending Cash Position of $124.50 Mil. The current Ending Cash Position is $124.50 Mil. Neurogene's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Neurogene (NGNE), the current Ending Cash Position is $124.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neurogene Business Description

Other Exchanges UU8:Germany
Address 535 W 24th Street, 5th Floor, New York, NY, USA, 10011
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
12GF Score

Get the complete analysis for NGNE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.90
Price